| Literature DB >> 26481684 |
Arvind Shakya1, Alon Goren2, Alex Shalek3, Cody N German1, Jeremy Snook1, Vijay K Kuchroo4, Nir Yosef4, Raymond C Chan5, Aviv Regev6, Matthew A Williams7, Dean Tantin7.
Abstract
Epigenetic changes are crucial for the generation of immunological memory. Failure to generate or maintain these changes will result in poor memory responses. Similarly, augmenting or stabilizing the correct epigenetic states offers a potential method of enhancing memory. Yet the transcription factors that regulate these processes are poorly defined. We find that the transcription factor Oct1 and its cofactor OCA-B are selectively required for the in vivo generation of CD4(+) memory T cells. More importantly, the memory cells that are formed do not respond properly to antigen reencounter. In vitro, both proteins are required to maintain a poised state at the Il2 target locus in resting but previously stimulated CD4(+) T cells. OCA-B is also required for the robust reexpression of multiple other genes including Ifng. ChIPseq identifies ∼50 differentially expressed direct Oct1 and OCA-B targets. We identify an underlying mechanism involving OCA-B recruitment of the histone lysine demethylase Jmjd1a to targets such as Il2, Ifng, and Zbtb32. The findings pinpoint Oct1 and OCA-B as central mediators of CD4(+) T cell memory.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26481684 PMCID: PMC4647264 DOI: 10.1084/jem.20150363
Source DB: PubMed Journal: J Exp Med ISSN: 0022-1007 Impact factor: 14.307
Figure 1.OCA-B localizes Jmjd1a to the (A) Naive mouse splenic CD4+ T cells were stimulated in vitro for 12 h and stained for CD44, CD62L, and intracellular OCA-B. Naive cells are shown as a control. (B) Western blots showing the time course of naive helper T cell polyclonal activation. OCA-B induction is shown, as is phospho-ERK1/2 status. Oct1, ERK1/2, and β-actin are shown as controls. (C) 100 µg of total primary T cell extract in RIPA buffer was used for IP with anti-Jmjd1a antibody or isotype control. OCA-B Western blot (WB) is shown. Endogenous proteins were used. 2.5% input is shown in lane 3. (D) Similar to C except 100 µg of total WT or Oct1 3T3 MEF extract in RIPA buffer was used. Human OCA-B was introduced by viral transduction. (E) ChIP-qPCR was performed at the Il2 promoter using purified naive T cells (Naive), 6-h-stimulated cells (Stim), cells stimulated for 2 d and cultured for 8 d in the absence of stimulus (Rested), or the same cells stimulated for 6 h (Re-stim). Antibodies specific to Oct1, Jmjd1a, Mta2 (NuRD), OCA-B, and H3K9me2 were used. Enrichment was calculated relative to a control genomic region, isotype control antibody, and standard input DNA. Values depict mean ± SD of three biological replicates. Differences in absolute levels of enrichment reflect variability in antibody properties. (F) WT and Ocab cells were stimulated for 6 h, and Il2 mRNA expression was assessed using TaqMan RT-qPCR. mRNA levels were normalized to β-actin. Triplicate results are shown ± SD. (G) Il2 mRNA expression was measured in Naive, Stim, Rested, or Re-stim WT and Ocab cells as in F. Expanding cells were additionally infected using MSCV (empty vector or encoding human OCA-B). Cells were not drug selected. Naive and Stim mRNA expression data are identical to F, except plotted on a different y axis. (H) Cells stimulated as in G were subjected to intracellular cytokine staining using antibodies against IL-2 and assessed by flow cytometry.
Figure 2.OCA-B coordinates the expression of multiple direct target genes in Re-stim primary CD4 (A) Mouse WT and Ocab primary CD4+ T cells were isolated, stimulated for 6 h, and prepared for RNAseq. Gene expression scatter plot is shown from the two cell types based on cufflinks. Il17a, Il2, Il3, and Ifng are highlighted for purposes of comparison with B. Significantly changed genes in B are shown in red. Displayed values are log10 (fragments per kilobase per million + 1). (B) Similar data (as in A) using Re-stim cells. Differentially expressed genes are marked in red. (C) RNAseq read densities across mouse Zap70 were plotted as custom tracks using the integrated genome viewer (IGV), confirming RNAseq quality and normalization. Naive, Stim, Rested, and Re-stim cells are shown ± OCA-B. (D) Read densities for Il2, Ifng, Il17a, Ly6a, and Zbtb32. (E) Gzmd and Prf1. (F) Ifng and Zbtb32 mRNA levels were assessed by RT-qPCR using primary T cells stimulated as in A and B in biological triplicate. Error bars depict ±SD. **, Student’s t test p-value ≤0.005. (G) Spearman correlation values were determined for the entire alignable RNAseq dataset and plotted as a dendrogram. (H) Overlapping target genes identified by ChIPseq using antibodies against Oct1 and OCA-B in Rested and Re-stim T cells. 3,750 enriched regions corresponding to 3,173 nearby genes were identified in the intersection between the two conditions (Rested and Re-stim T cells) and two antibodies (Oct1 and OCA-B). (I) IGV images of Oct1 and OCA-B ChIPseq read densities in Rested and Re-stim T cells. (J) ChIP-qPCR using the mouse Il2, Ifng, and Zbtb32 promoter regions and an area downstream of Ifng. Enrichment over background for Oct1, H3K9me2, and OCA-B is shown in Rested and Re-stim WT and Ocab primary CD4+ T cells. Values depict mean ± SD of three biological replicates. (K) Schematic and DNA sequence of two regions enriched by ChIPseq. (top) Element identified between Ifng and the Tmevpg1 lncRNA containing a dyad octamer motif conserved to humans. (bottom) Conserved element upstream of Zbtb32. Yellow highlighting indicates conserved nucleotides. Bold indicates canonical octamer motif.
Top differentially down-regulated genes in Re-stim OCA-B/Pou2af1-deficient T cells relative to WT
| No. | Gene | Description | Fold restimulation | Target in combined ChIPseq? |
|---|---|---|---|---|
| 1 | chemokine (C-C motif) ligand 1 | −9.01 | ||
| 2 | granzyme B | −8.92 | ||
| 3 | interleukin 9 | −8.57 | ||
| 4 | interferon gamma | −8.49 | Yes | |
| 5 | Preproenkephalin | −8.38 | ||
| 6 | interleukin 3 | −7.19 | ||
| 7 | interleukin 5 | −7.04 | Yes | |
| 8 | interleukin 22 | −6.43 | ||
| 9 | interleukin 17A | −6.33 | ||
| 10 | chemokine (C-C motif) ligand 4 | −5.63 | ||
| 11 | inhibin beta-A | −5.30 | ||
| 12 | interleukin 2 | −5.00 | Yes | |
| 13 | chemokine (C-C motif) ligand 3 | −4.91 | Yes | |
| 14 | interleukin 13 | −4.49 | ||
| 15 | interleukin 24 | −4.49 | ||
| 16 | interleukin 10 | −4.45 | Yes | |
| 17 | lymphocyte activation gene 3 | −4.34 | Yes | |
| 18 | zinc finger and BTB domain containing 32 | −4.16 | Yes | |
| 19 | chemokine (C-X-C motif) ligand 2 | −4.16 | ||
| 20 | cellular retinoic acid binding protein II | −4.09 | Yes | |
| 21 | interleukin 6 | −4.06 | ||
| 22 | T cell immunoreceptor with Ig and ITIM domains | −3.70 | ||
| 23 | tissue inhibitor of metalloproteinase 1 | −3.65 | ||
| 24 | regulator of G-protein signaling 1 | −3.56 | Yes | |
| 25 | ERO1-like ( | −3.56 | ||
| 26 | RIKEN cDNA 0610010O12 gene | −3.52 | ||
| 27 | serine (or cysteine) peptidase inhibitor, clade B, member 6b | −3.50 | Yes | |
| 28 | colony stimulating factor 2 (granulocyte-macrophage) | −3.34 | Yes | |
| 29 | interleukin 4 | −3.33 | ||
| 30 | tumor necrosis factor receptor superfamily, member 4 | −3.22 | Yes | |
| 31 | SLAM family member 7 | −3.21 | Yes | |
| 32 | chemokine (C-C motif) ligand 7 | −3.20 | ||
| 33 | interleukin 21 | −3.18 | Yes | |
| 34 | EGL nine homolog 3 ( | −3.17 | Yes | |
| 35 | chemokine (C-C motif) ligand 20 | −3.12 | ||
| 36 | cytokine inducible SH2 containing protein | −3.06 | Yes | |
| 37 | interleukin 17F | −3.06 | ||
| 38 | interleukin 31 | −3.00 | Yes | |
| 39 | interleukin 2 receptor, alpha chain | −2.96 | Yes | |
| 40 | serine (or cysteine) peptidase inhibitor, clade B, member 9 | −2.95 | Yes | |
| 41 | oncostatin M | −2.93 | Yes | |
| 42 | basic leucine zipper transcription factor, ATF-like | −2.89 | Yes | |
| 43 | family with sequence similarity 132, member A | −2.77 | ||
| 44 | asparagine synthetase | −2.73 | ||
| 45 | −2.71 | |||
| 46 | WNT1 inducible signaling pathway protein 2 | −2.69 | ||
| 47 | caspase 6 | −2.65 | ||
| 48 | tumor necrosis factor (ligand) superfamily, member 8 | −2.59 | Yes | |
| 49 | chemokine (C-X-C motif) ligand 3 | −2.56 | ||
| 50 | interleukin 27 | −2.52 | ||
| 51 | HemK methyltransferase family member 1 | −2.49 | Yes | |
| 52 | CD200 antigen | −2.42 | Yes | |
| 53 | cDNA sequence | −2.43 | ||
| 54 | neuritin 1 | −2.42 | Yes | |
| 55 | Cytotoxic T lymphocyte associated protein 4 | −2.39 | Yes | |
| 56 | T-box 21 | −2.37 | Yes | |
| 57 | 1-acylglycerol-3-phosphate | −2.21 | ||
| 58 | lymphoid-restricted membrane protein | −2.21 | Yes | |
| 59 | CD70 antigen | −2.18 | ||
| 60 | chemokine (C motif) ligand 1 | −2.17 | ||
| 61 | RIKEN cDNA 0610007P14 gene | −2.13 | Yes | |
| 62 | basic leucine zipper transcription factor, ATF-like 2 | −2.12 | ||
| 63 | acyl-CoA thioesterase 7 | −2.08 | Yes | |
| 64 | Rho GDP dissociation inhibitor (GDI) gamma | −1.99 | ||
| 65 | chemokine (C-C motif) receptor 8 | −1.97 | Yes | |
| 66 | abhydrolase domain containing 14A | −1.96 | ||
| 67 | tumor necrosis factor (ligand) superfamily, member 14 | −1.94 | ||
| 68 | heparin-binding EGF-like growth factor | −1.91 | ||
| 69 | stanniocalcin 2 | −1.89 | ||
| 70 | zinc finger E-box binding homeobox 2 | −1.86 | ||
| 71 | phospholipase A2, group XIIA | −1.86 | ||
| 72 | TNFAIP3 interacting protein 3 | −1.78 | ||
| 73 | aminoacylase 1 | −1.75 | ||
| 74 | glutathione S-transferase, theta 2 | −1.74 | Yes | |
| 75 | small proline rich protein 2E | −1.72 | ||
| 76 | signal transducer and activator of transcription 5A | −1.70 | Yes | |
| 77 | galactokinase 1 | −1.68 | Yes | |
| 78 | stromal cell–derived factor 4 | −1.68 | Yes | |
| 79 | mitochondrial ribosomal protein S2 | −1.65 | ||
| 80 | Translocase of inner mitochondrial membrane 10 | −1.62 | ||
| 81 | interleukin 12 receptor, beta 1 | −1.60 | Yes | |
| 82 | solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 | −1.60 | ||
| 83 | ST6 (alpha- | −1.58 | ||
| 84 | recombining binding protein suppressor of hairless ( | −1.56 | ||
| 85 | WNT1 inducible signaling pathway protein 1 | −1.56 | Yes | |
| 86 | ets variant gene 6 (TEL oncogene) | −1.55 | Yes | |
| 87 | polymerase (RNA) III (DNA directed) polypeptide G | −1.55 | ||
| 88 | amphiregulin | −1.54 | ||
| 89 | HIRA interacting protein 3 | −1.52 | Yes | |
| 90 | TLC domain containing 1 | −1.52 | Yes | |
| 91 | pleomorphic adenoma gene-like 2 | −1.51 | Yes | |
| 92 | N-myc downstream regulated gene 1 | −1.50 | ||
| 93 | inducible T cell co-stimulator | −1.50 | Yes | |
| 94 | myelocytomatosis oncogene | −1.38 | Yes | |
| 95 | cyclin D2 | −1.37 | Yes | |
| 96 | recombination signal binding protein for immunoglobulin kappa J region | −1.36 | Yes | |
| 97 | macrophage migration inhibitory factor | −1.29 | ||
| 98 | elongation factor RNA polymerase II 2 | −1.28 | ||
| 99 | pyrophosphatase (inorganic) 1 | −1.24 | ||
| 100 | coenzyme Q4 homolog (yeast) | −1.17 | ||
| 101 | leucine aminopeptidase 3 | −1.17 | ||
| 201 | growth arrest and DNA damage-inducible 45 beta | −1.13 | Yes | |
| 103 | endothelial cell-specific chemotaxis regulator | −1.13 | ||
| 104 | coiled-coil-helix-coiled-coil-helix domain containing 4 | −1.09 | Yes | |
| 105 | activating transcription factor 3 | −1.07 | Yes | |
| 106 | ladinin | −1.04 | ||
| 107 | transmembrane protein 97 | −1.03 | ||
| 108 | heat shock protein 5 | −1.02 | Yes | |
| 109 | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide | −1.02 | Yes | |
| 110 | RIKEN cDNA 1810029B16 gene | −1.01 |
Included are genes normally induced by twofold or greater upon restimulation, showing twofold or greater down-regulation in the absence of OCA-B. See Table S2 for full dataset. Empty cells in the last column indicate “No,” although some genes may have just missed the arbitrary threshold and would be false negatives.
Merged data for ChIPseq binding of Oct1 and OCA-B in rested and restimulated T cells.
Figure 3.Oct1 and OCA-B associate with cell type–nonspecific genes. (A) IGV images of ChIPseq output for the Hist1h histone gene cluster. Peak calling is shown on the right. (B) Polr2a (encoding the RNA Pol II large subunit). (C) Taf12 (encoding a component of the TFIID transcription complex).
Figure 4.Supplemental IL-2 does not complement OCA-B deficiency. (A) WT and Ocab naive CD4+ T cells were stimulated with CD3ε and CD28 antibodies for 2 d. The cells were rested for 8 d either in the presence or absence of 30 IU/ml exogenously added IL-2. Cells were restimulated with the same antibodies for 6 h. Re-stim cells were stained for CD4 and intracellular cytokines. Intracellular expression of IL-2 is shown. (B) Mean of IL-2 expression from four sets of T cells independently purified from separate mice. Percentage of cytokine producing cells is plotted. Mean of quadruplicate results is shown ± SD. **, Student’s t test p-value ≤0.005; ***, p-value ≤0.0001. (C) Similar quantification (as in B) of IFNγ and TNF expression.
Figure 5.OCA-B is required for robust memory CD4 (A) WT SMARTA (Thy1.1+) T cells were transferred into Thy1.2+ mice, which were infected with LCMV 1 d later. Splenocytes were harvested at the indicated time points after infection. Cells were stained with OCA-B antibodies and subjected to flow cytometry. Enrichment relative to host T cells is shown. (B) Ocab SMARTA (Thy1.2+Ly5.2+) and WT control SMARTA (Thy1.1+Thy1.2+Ly5.2+) T cells were co-transferred into Ly5.1+ mice, which were infected with LCMV. Frequencies of each population were tracked at the indicated time points. Representative plots, gated on donor SMARTA cells, indicate the relative distribution of WT and Ocab SMARTA T cells in the spleen at the peak of the primary response (Primary, 8 d after infection), after the establishment of memory (Memory, 38 d after infection), or 7 d after rechallenge with Lm-gp61 (Memory recall). (C) For each time point, the ratio of Ocab to WT SMARTA blood cells was calculated for each of five mice. (D) For each time point, total splenic CD4+ Ocab and WT SMARTA T cell numbers were averaged and plotted. Three animals were sacrificed at days 8 and 38, and four animals at day 38 + 7. Error bars depict ±SD. (E) Cells isolated as in D were stained using the indicated antibodies and analyzed by flow cytometry. Cells were gated for viability and CD4 expression. (F) The ratio of IFNγ mean fluorescence intensities (MFIs) in WT and Ocab SMARTA T cells was calculated from each of five mice and plotted as mean ± SD. Cells were stimulated with peptide/brefeldin-A ex vivo before intracellular cytokine staining. (G) Similar calculation (as in F) using IL-2 MFIs. (H) WT (Thy1.1+) and Ocab (Thy1.1+Thy1.2+) SMARTA cells were combined and adoptively transferred into Thy1.2 recipients. After LCMV infection, cohorts of four mice were sacrificed at 8, 42, 77, and 100 d. T cell numbers at peak response were averaged. For each genotype, T cell counts were divided by the number at peak response and averaged. Error bars depict ± SD.
Figure 6.Germline Oct1 loss impairs CD4 memory. (A) Naive CD4+ T cells were isolated from spleens of Rag1 mice engrafted with Oct1 SMARTA (Thy1.1+Thy1.2+) fetal liver or WT SMARTA control (Thy1.1+). Isolated cells were combined 1:1 and adoptively transferred into Thy1.2+ recipients, which were then infected with LCMV. Flow cytometry plots are shown of splenic CD4+ T cells at peak response (8 d), after the establishment of memory (42 d), and after rechallenge with Lm-gp61 (42 + 7 d). Data from a single mouse representative of five examples are shown. For each plot (gated on CD4), host T cells (Thy1.2+), WT transferred T cells (Thy1.1+), and Oct1-deficient transferred T cells (Thy1.1/1.2+) are shown. (B) Quantification of averaged relative T cell numbers from five mice. Error bars depict ±SD. (C) Same calculation as in B except using IFNγ/IL-2 double producers.
Figure 7.Conditional loss of Oct1 in T cells impairs CD4 memory. (A) Generation of Oct1 (Pou2f1) conditional mice. (top) Oct1 targeting event. (bottom) Agarose gel showing PCR data from chimera generated by ESC blastocyst injection (lane 1). Breeding generated a germline transmittant founder (lane 4). Targeted ESCs are shown as a control (lane 9). (B, left) After deletion of the LacZ reporter by breeding onto a germline FLIP recombinase expressing mouse, a conditional allele was generated in which loxP sites flank Oct1 exon 6, which encodes part of the DNA binding domain. (right) Genotyping of representative WT, floxed, and null alleles. (C) Oct1 protein levels were measured in CD4+ T cells purified from Oct1;CD4-cre and control Oct1;CD4-cre mice by Western blot. Purity was ∼90%. (D, top) CD4+/CD8+ thymocyte profiles from 8-wk-old Oct1 conditional-sufficient or -deficient mice and WT control. (bottom) CD4+/CD8+ splenic T cell profiles from the same mice. (E) Similar data (as in D) from 35-wk-old mice. (F) Oct1;CD4-cre and control Oct1;CD4-cre splenic naive CD4+ T cells were stimulated in vitro, rested, and restimulated. Il2 mRNA levels were monitored by TaqMan RT-qPCR. Means of replicates from T cells taken from three individual mice of each genotype are shown ± SD. (G) Oct1;CD4-cre mice were infected with LCMV, rested for either 77 or 140 d, and subsequently rechallenged using Lm-gp61. For each of the two rechallenge time points, splenic CD4+ cells were isolated by magnetic separation, stained with I-Ab/gp66–77 tetramers, and FACS sorted, and the conditional (floxed) allele was detected by qPCR. Loss was measured relative to tail DNA from the same mouse. Means of three mice ± SD are shown. (H) LCMV-reactive CD4+ T cells were assessed using mixed radiation chimeras in which lethally irradiated Thy1.1 host mice were repopulated with Ly5.2;Thy1.2 bone marrow from either Oct1 or Oct1 mice. Bone marrow was mixed 1:1 with WT Ly5.1;Thy1.2 control bone marrow. Oct1 and control Oct1 T cells are shown after infection with LCMV (8 and 42 d) or rechallenge with Lm-gp61 (42 + 7 d) next to the WT competitor cells from the same mouse. (I) For each mouse (n = 4–5), the ratio of I-Ab/gp66–77 tetramer–positive cells for each genotype (WT/test) was calculated. Mean of ratios ± SD is plotted. The Mann–Whitney test was used to compare WT and test populations at each time point (p-values: 8 d = 0.3429; 42 d = 0.4206; *, 42 + 7 d = 0.0159).